Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-033: Pembrolizumab vs Docetaxel in Previously Treated PD-L1+ NSCLC
NCT02864394Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2016
- Primary completion
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02864394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864394.